Kestra Advisory Services’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$249K Sell
3,757
-7,846
-68% -$460K ﹤0.01% 2932
2026
Q1
$628K Buy
11,603
+8,903
+330% +$496K ﹤0.01% 2052
2025
Q4
$151K Buy
+2,700
New +$140K ﹤0.01% 3116
2022
Q3
Sell
-9,521
Closed -$400K 2252
2022
Q2
$400K Buy
+9,521
New +$399K ﹤0.01% 1454
2021
Q1
Sell
-29,864
Closed -$1.54M 2080
2020
Q4
$1.54M Buy
+29,864
New +$1.43M 0.02% 687

Other funds holding XPH

Kestra Advisory Services's XPH Position: Q2 2026 in Review

Kestra Advisory Services reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 68% in Q2 2026, selling an estimated $460K and leaving 3,757 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #2932.

Kestra Advisory Services first reported a position in XPH in Q4 2020 and has held it in 5 quarters since. The position peaked at $1.54M in Q4 2020. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

  • Kestra Advisory Services held 3,757 shares of State Street SPDR S&P Pharmaceuticals ETF worth $249K as of Q2 2026.
  • Kestra Advisory Services sold 7,846 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $460K.
  • State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #2932 holding.
  • Kestra Advisory Services first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2020 and has held it in 5 quarters since.
  • Kestra Advisory Services's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1.54M in Q4 2020.
  • 93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.